Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted.
To read our insight into the cost of pharma M&A click here or for R&D innovation click here.
Media
Takeda’s takeover of Shire (CNBC)
Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted.
To read our insight into the cost of pharma M&A click here or for R&D innovation click here.
Related
Media
How R&D Teams Create Value from On-Market Products (MedNous)
DiscoverHow European MidPharmas have Grown Profits (MedNous)
DiscoverAstraZeneca sacrifices revenue with a no-profit Covid-19 vaccine (Daily Mail)
Discover